What is Pacira BioSciences' operating income?

Pacira BioSciences' total operating income in 2025 was $19.19 million, based on the following breakdown: Total Gross Profit: $576.66 million Total Operating Expenses: $557.47 million

Pacira BioSciences (PCRX) Financials

$24.67 +0.84 (+3.52%)

As of 08/21/2026 04:00 PM Eastern

Compare

Annual Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	1.86	-38	-43	-0.47	-11	146	42	-15	42	-100	7.03
Consolidated Net Income / (Loss)	1.86	-38	-43	-0.47	-11	146	42	32	42	-100	7.03
Net Income / (Loss) Continuing Operations	1.86	-38	-43	-0.47	-11	146	42	-15	42	-100	7.03
Total Pre-Tax Income	2.12	-38	-42	-0.43	-11	20	56	27	62	-63	17
Total Operating Income	9.46	-32	-25	16	10	46	90	60	88	-73	19
Total Gross Profit	177	166	199	250	314	312	401	1,134	490	531	577
Total Revenue	249	276	287	337	421	430	542	1,334	675	701	726
Operating Revenue	249	276	287	337	421	430	542	1,334	675	701	726
Total Cost of Revenue	72	110	88	87	107	117	140	199	185	170	150
Operating Cost of Revenue	72	110	88	87	107	117	140	199	185	170	150
Total Operating Expenses	168	198	224	235	304	266	311	1,061	403	604	557
Selling, General & Admin Expense	139	153	161	177	201	194	199	255	269	294	369
Research & Development Expense	29	46	57	56	72	59	56	85	76	82	117
Amortization Expense	-	-	0.00	0.00	5.70	7.87	14	115	57	57	57
Impairment Charge	-	-	-	-	-	5.17	-	0.00	0.00	163	0.00
Restructuring Charge	-	-	4.87	1.56	25	-	-	-	-0.35	7.70	14
Total Other Income / (Expense), net	-7.34	-5.82	-18	-16	-21	-26	-34	-93	-26	10	-2.32
Interest Expense	7.78	7.06	22	22	24	34	32	40	37	9.05	18
Interest & Investment Income	0.68	1.32	4.08	6.50	7.38	4.63	0.90	4.54	11	20	23
Other Income / (Expense), net	-0.24	-0.08	0.17	-0.89	-4.98	2.85	-2.67	-58	-0.19	-0.37	-6.62
Income Tax Expense	0.26	0.11	0.14	0.05	0.27	-125	14	-5.21	20	36	9.84
Basic Earnings per Share	$0.05	($1.02)	($1.07)	($0.01)	($0.27)	$3.41	$0.95	$0.35	$0.91	($2.15)	$0.16
Weighted Average Basic Shares Outstanding	36.54M	37.24M	39.81M	40.91M	41.51M	42.67M	44.26M	45.52M	46.22M	46.25M	44.57M
Diluted Earnings per Share	$0.04	($1.02)	($1.07)	($0.01)	($0.27)	$3.33	$0.92	$0.34	$0.89	($2.15)	$0.16
Weighted Average Diluted Shares Outstanding	41.30M	37.24M	39.81M	40.91M	41.51M	43.68M	45.63M	46.54M	51.98M	46.25M	45.04M
Weighted Average Basic & Diluted Shares Outstanding	37.10M	37.24M	39.81M	40.91M	41.51M	43.86M	44.85M	45.95M	46.50M	46.28M	40.49M

This table shows Pacira BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-7.74	8.98	19	-143	-289	4.81	-4.85	5.43	1.64	2.92	4.65
Consolidated Net Income / (Loss)	67	8.98	19	-143	-84	4.81	-4.85	5.43	1.64	2.92	4.65
Net Income / (Loss) Continuing Operations	-7.74	8.98	19	-143	-289	4.81	-4.85	5.43	1.64	2.92	4.65
Total Pre-Tax Income	95	14	37	-139	-38	8.71	-1.93	9.52	0.57	5.00	2.56
Total Operating Income	33	13	28	-140	25	1.99	8.50	6.36	2.34	6.90	4.27
Total Gross Profit	809	120	134	130	848	135	140	145	157	141	148
Total Revenue	856	167	178	169	888	169	181	180	197	177	192
Operating Revenue	856	167	178	169	888	169	181	180	197	177	192
Total Cost of Revenue	48	47	44	39	40	34	41	34	40	36	44
Operating Cost of Revenue	48	47	44	39	40	34	41	34	40	36	44
Total Operating Expenses	745	106	106	269	1,110	133	132	139	154	134	144
Selling, General & Admin Expense	66	72	68	74	80	87	89	92	102	94	92
Research & Development Expense	19	18	20	19	24	25	28	26	38	28	30
Amortization Expense	72	14	14	14	72	14	14	14	14	14	14
Other Operating Expenses / (Income)	-	-	2.74	-	-	6.19	0.63	-	-	-2.28	7.59
Total Other Income / (Expense), net	-42	0.43	8.34	0.67	19	6.72	-10	3.16	-1.77	-1.90	-1.71
Interest Expense	20	3.32	-3.63	4.69	-2.84	4.58	4.70	5.26	3.89	3.70	3.62
Interest & Investment Income	3.43	3.90	4.75	5.48	5.56	6.90	5.01	8.53	2.30	1.93	1.94
Other Income / (Expense), net	-25	-0.16	-0.04	-0.12	10	4.40	-11	-0.11	-0.17	-0.14	-0.03
Income Tax Expense	29	4.66	18	4.61	46	3.89	2.92	4.09	-1.07	2.08	-2.10
Basic Earnings per Share	$0.55	$0.19	$0.41	($3.11)	$0.36	$0.10	($0.11)	$0.12	$0.05	$0.07	$0.12
Weighted Average Basic Shares Outstanding	46.22M	46.50M	46.17M	46.13M	46.25M	46.28M	45.46M	44.04M	44.57M	40.46M	39.46M
Diluted Earnings per Share	$0.58	$0.19	$0.39	($3.11)	$0.38	$0.10	($0.11)	$0.12	$0.05	$0.07	$0.12
Weighted Average Diluted Shares Outstanding	51.98M	52.19M	50.54M	46.13M	46.25M	46.53M	45.46M	44.46M	45.04M	40.91M	40.30M
Weighted Average Basic & Diluted Shares Outstanding	46.50M	46.55M	46.13M	46.17M	46.28M	46.30M	44.93M	43.02M	40.49M	39.35M	39.86M

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	19	-21	18	78	-54	22	486	-481	49	123	-118
Net Cash From Operating Activities	28	33	18	49	71	77	126	145	155	189	152
Net Cash From Continuing Operating Activities	28	33	18	49	71	77	126	145	155	189	152
Net Income / (Loss) Continuing Operations	1.86	-38	-43	-0.47	-11	146	42	16	42	-100	7.03
Consolidated Net Income / (Loss)	1.86	-38	-43	-0.47	-11	146	42	16	42	-100	7.03
Depreciation Expense	11	13	14	13	20	20	29	92	76	79	91
Amortization Expense	4.58	4.57	12	13	15	18	26	7.21	-0.83	-4.20	-1.93
Non-Cash Adjustments To Reconcile Net Income	33	32	37	34	39	41	45	85	67	209	90
Changes in Operating Assets and Liabilities, net	-23	22	-2.57	-11	7.90	-147	-16	-54	-29	5.07	-34
Net Cash From Investing Activities	-19	-62	-224	21	-128	-278	-21	-225	78	-83	99
Net Cash From Continuing Investing Activities	-19	-62	-224	21	-128	-278	-21	-225	78	-83	99
Purchase of Property, Plant & Equipment	-40	-25	-19	-15	-10	-38	-46	-30	-15	-11	-15
Acquisitions	0.00	0.00	-15	0.00	-118	0.00	-420	-	0.00	0.00	-17
Purchase of Investments	-189	-193	-503	-363	-320	-548	-629	-401	-144	-252	-142
Sale and/or Maturity of Investments	217	172	322	405	319	308	1,078	238	237	180	274
Net Cash From Financing Activities	11	7.26	224	8.95	3.67	222	381	-402	-183	17	-370
Net Cash From Continuing Financing Activities	11	7.26	224	8.95	3.67	222	381	-402	-183	17	-370
Repayment of Debt	-1.47	0.00	-129	0.00	-0.34	-189	0.00	-428	-336	-211	-318
Repurchase of Common Equity	-	-	-	-	-	-	-4.55	-1.18	-1.16	-34	-151
Issuance of Debt	0.00	0.00	345	0.00	0.00	369	364	0.00	150	288	101
Issuance of Common Equity	2.09	1.50	1.86	1.78	2.40	2.55	2.81	2.95	2.81	2.30	2.80
Other Financing Activities, net	10	5.77	6.49	7.17	1.61	40	19	24	1.83	-27	-5.12
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-	0.00	0.00	-0.08
Cash Interest Paid	4.22	3.85	6.90	8.21	8.20	7.21	7.00	33	28	15	15

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	54	31	63	-1.09	31	6.84	17	-153	11	-14	62
Net Cash From Operating Activities	48	49	53	54	33	35	12	61	44	26	57
Net Cash From Continuing Operating Activities	48	49	53	54	33	35	12	61	44	26	57
Net Income / (Loss) Continuing Operations	25	8.98	19	-143	16	4.81	-4.85	5.43	1.64	2.92	4.65
Consolidated Net Income / (Loss)	25	8.98	19	-143	16	4.81	-4.85	5.43	1.64	2.92	4.65
Depreciation Expense	18	18	19	20	21	21	27	21	21	21	21
Amortization Expense	0.71	0.71	0.79	0.86	0.87	-1.04	0.87	0.68	-4.35	0.01	0.88
Non-Cash Adjustments To Reconcile Net Income	12	13	5.04	176	15	8.67	26	41	14	14	15
Changes in Operating Assets and Liabilities, net	-8.62	7.77	9.66	-0.04	-20	1.86	-38	-7.30	11	-12	16
Net Cash From Investing Activities	8.37	-16	-15	-52	-0.37	-26	62	44	19	19	12
Net Cash From Continuing Investing Activities	8.37	-16	-15	-52	-0.37	-26	62	44	19	19	12
Purchase of Property, Plant & Equipment	-1.80	-2.84	-1.59	-4.09	-2.12	-8.55	-2.70	-3.87	-0.22	-2.72	-1.34
Purchase of Investments	-26	-56	-50	-101	-45	-70	-6.31	-39	-28	0.00	-3.91
Sale and/or Maturity of Investments	36	43	36	53	47	69	71	86	47	23	17
Net Cash From Financing Activities	-1.78	-2.82	25	-2.85	-1.96	-2.99	-58	-257	-52	-59	-7.65
Net Cash From Continuing Financing Activities	-1.78	-2.82	25	-2.85	-1.96	-2.99	-58	-257	-52	-59	-7.65
Repayment of Debt	-2.81	-2.81	-202	-2.81	-2.81	-2.81	-3.75	-306	-5.00	-5.00	-5.00
Repurchase of Common Equity	-	-	-34	-	-	0.00	-	-52	-48	-50	-1.34
Other Financing Activities, net	-0.11	-0.00	-27	-0.03	-0.08	-0.18	-5.29	0.00	0.35	-4.35	-3.04
Cash Interest Paid	2.70	3.97	3.02	3.20	5.23	2.72	4.97	2.70	4.85	1.60	4.58
Cash Income Taxes Paid	2.29	-0.25	4.91	4.91	1.45	0.29	7.95	0.71	-	0.05	0.86

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	388	391	628	689	831	1,275	2,075	1,681	1,574	1,554	1,265
Total Current Assets	253	243	391	478	409	652	866	498	510	745	548
Cash & Equivalents	57	36	54	133	78	100	586	104	153	277	159
Short-Term Investments	102	137	257	251	214	422	71	185	125	208	80
Accounts Receivable	26	30	32	38	48	53	96	98	106	113	124
Inventories, net	62	31	41	49	58	65	99	96	104	125	153
Prepaid Expenses	6.12	9.28	6.69	7.95	11	12	15	15	22	22	33
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	-	-	0.00
Plant, Property, & Equipment, net	90	101	107	109	105	137	188	184	174	167	141
Total Noncurrent Assets	45	47	130	103	318	486	1,021	999	890	641	576
Long-Term Investments	13	0.00	74	41	65	95	22	64	38	36	22
Goodwill	31	47	55	62	100	100	145	163	163	0.00	20
Intangible Assets	0.08	-	-	0.00	104	97	624	541	483	426	368
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	0.00	106	153	160	144	130	124
Other Noncurrent Operating Assets	0.41	0.62	0.83	0.00	49	89	76	71	61	49	42
Total Liabilities & Shareholders' Equity	388	391	628	689	831	1,275	2,075	1,681	1,574	1,554	1,265
Total Liabilities	169	172	349	368	476	655	1,345	906	704	775	572
Total Current Liabilities	150	45	56	61	108	253	521	148	97	310	121
Accounts Payable	8.74	7.51	15	14	13	10	11	15	16	19	15
Accrued Expenses	35	37	41	46	70	71	128	90	64	80	96
Other Current Liabilities	-	-	-	0.00	23	22	7.89	9.12	8.80	8.89	9.84
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	-	0.00
Total Noncurrent Liabilities	20	128	293	307	368	401	824	758	607	465	451
Long-Term Debt	0.00	109	276	291	306	313	675	656	514	384	372
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	-	0.00	4.21
Other Noncurrent Operating Liabilities	11	19	16	17	62	88	149	103	93	82	75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	218	219	279	321	355	620	730	775	870	778	693
Total Preferred & Common Equity	218	219	279	321	355	620	730	775	870	778	693
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	218	219	279	321	355	620	730	775	870	778	693
Common Stock	527	565	669	710	754	873	942	924	977	1,009	1,065
Retained Earnings	-308	-346	-389	-388	-399	-254	-212	-149	-107	-206	-199
Treasury Stock	-	-	-	-	-	-	-	-	0.00	-25	-177
Accumulated Other Comprehensive Income / (Loss)	-0.05	-0.03	-0.45	-0.28	0.32	0.32	0.17	-0.38	0.25	0.34	4.33

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	1,523	1,542	1,534	1,583	1,647	1,522	1,587	1,537	1,298	1,209	1,244
Total Current Assets	376	429	447	543	632	690	760	746	563	515	615
Cash & Equivalents	36	87	99	184	247	246	284	300	148	144	206
Short-Term Investments	138	134	136	142	157	208	210	145	99	58	45
Accounts Receivable	93	99	97	102	105	101	105	114	115	126	132
Inventories, net	93	92	97	97	103	112	134	148	158	150	135
Prepaid Expenses	16	17	19	19	20	24	28	37	43	37	30
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	-	-	67
Plant, Property, & Equipment, net	182	180	176	172	169	167	164	155	147	136	130
Total Noncurrent Assets	966	933	911	868	846	665	662	636	587	557	498
Long-Term Investments	8.28	36	36	37	36	37	28	19	20	23	24
Goodwill	163	163	163	163	163	0.00	22	20	20	20	20
Intangible Assets	526	512	498	469	455	440	435	423	382	353	285
Noncurrent Deferred & Refundable Income Taxes	168	156	152	141	135	134	129	128	120	122	125
Other Noncurrent Operating Assets	100	66	63	59	56	54	49	47	44	39	45
Total Liabilities & Shareholders' Equity	1,523	1,542	1,534	1,583	1,647	1,522	1,587	1,537	1,298	1,209	1,244
Total Liabilities	755	734	703	691	768	772	788	779	570	555	572
Total Current Liabilities	99	109	94	93	93	306	315	313	107	109	122
Accounts Payable	17	24	17	8.98	19	19	23	30	18	14	18
Accrued Expenses	62	56	60	67	65	76	80	71	80	85	93
Other Current Liabilities	8.95	8.98	8.63	9.00	9.15	9.19	9.41	9.62	9.75	9.82	10
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	-	0.71
Total Noncurrent Liabilities	657	625	609	598	675	466	473	466	463	446	450
Long-Term Debt	543	532	516	512	589	386	381	378	377	368	363
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	7.00	4.58	4.59	4.09	4.07
Other Noncurrent Operating Liabilities	114	93	93	86	86	80	85	84	82	74	83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	768	808	832	892	879	750	799	758	727	654	672
Total Preferred & Common Equity	768	808	832	892	879	750	799	758	727	654	672
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	768	808	832	892	879	750	799	758	727	654	672
Common Stock	936	951	963	990	983	996	1,024	1,036	1,050	1,074	1,088
Retained Earnings	-168	-143	-132	-98	-79	-222	-202	-206	-201	-196	-192
Treasury Stock	-	-	-	-	-25	-25	-25	-76	-126	-227	-227
Accumulated Other Comprehensive Income / (Loss)	-0.14	-0.17	-0.01	0.15	0.11	0.68	1.35	4.06	4.12	3.46	3.24

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	43,021,275.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	43,021,275.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.16
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.97%	10.99%	3.71%	17.67%	24.83%	2.05%	26.04%	146.27%	1.22%	3.85%	3.63%
EBITDA Growth	180.42%	-157.84%	105.02%	5,484.60%	-1.12%	115.54%	62.21%	-28.92%	39.83%	-86.84%	11,974.11%
EBIT Growth	263.25%	-448.26%	22.85%	160.67%	-63.37%	793.93%	77.35%	-97.69%	2,954.37%	-203.19%	117.05%
NOPAT Growth	328.95%	-370.81%	22.13%	163.82%	-34.15%	4,476.82%	-80.07%	7.26%	-16.95%	-186.15%	115.58%
Net Income Growth	113.53%	-2,144.67%	-12.28%	98.89%	-2,238.85%	1,421.01%	-71.15%	-24.21%	163.72%	-337.30%	107.07%
EPS Growth	110.26%	-2,650.00%	-4.90%	99.07%	-2,600.00%	1,333.33%	-72.37%	-63.04%	161.76%	-341.57%	107.44%
Operating Cash Flow Growth	5.48%	19.39%	-46.84%	174.78%	44.30%	9.23%	63.20%	15.56%	6.45%	22.46%	-19.75%
Free Cash Flow Firm Growth	-73.66%	45.03%	-19.07%	80.33%	-1,588.67%	260.50%	-425.64%	110.82%	55.15%	89.20%	-74.09%
Invested Capital Growth	63.68%	3.41%	9.88%	10.32%	61.81%	52.92%	136.70%	0.93%	-3.23%	-21.58%	-4.60%
Revenue Q/Q Growth	3.12%	1.31%	2.20%	4.99%	6.94%	2.03%	5.50%	0.00%	102.79%	101.73%	-48.76%
EBITDA Q/Q Growth	-24.91%	-11.42%	105.67%	7.00%	-17.14%	26.57%	-4.35%	0.00%	3.05%	28.86%	-27.14%
EBIT Q/Q Growth	-48.78%	-5.38%	30.75%	31.61%	-67.21%	59.09%	-14.60%	0.00%	39.83%	1.91%	-72.26%
NOPAT Q/Q Growth	-52.05%	-5.43%	30.47%	31.34%	-81.95%	-64.95%	-21.74%	0.00%	89.70%	-13.04%	-72.50%
Net Income Q/Q Growth	-81.73%	-4.04%	16.74%	88.68%	-610.71%	15.38%	-31.88%	0.00%	1,101.63%	-119.46%	109.00%
EPS Q/Q Growth	-85.71%	-5.15%	18.94%	88.89%	-640.00%	16.84%	-34.75%	0.00%	641.67%	-10.26%	-67.35%
Operating Cash Flow Q/Q Growth	8.82%	1.07%	-2.30%	9.62%	7.11%	36.90%	-15.72%	0.00%	3.72%	-7.09%	7.46%
Free Cash Flow Firm Q/Q Growth	2.28%	14.73%	-19.30%	60.93%	-51.46%	-77.98%	-1,397.82%	-87.85%	109.06%	-6.61%	22.73%
Invested Capital Q/Q Growth	0.30%	-3.40%	4.59%	0.05%	1.26%	0.06%	117.36%	0.00%	-0.91%	-0.35%	-3.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.15%	60.16%	69.33%	74.25%	74.65%	72.69%	74.10%	85.06%	86.32%	87.84%	79.39%
EBITDA Margin	10.15%	-5.29%	0.26%	12.15%	9.63%	20.33%	26.17%	7.55%	10.43%	1.32%	14.00%
Operating Margin	3.80%	-11.59%	-8.70%	4.72%	2.49%	10.79%	16.61%	4.50%	6.49%	-5.23%	2.64%
EBIT Margin	3.70%	-11.62%	-8.64%	4.46%	1.31%	11.45%	16.11%	0.15%	4.56%	-4.53%	1.73%
Profit (Net Income) Margin	0.75%	-13.73%	-14.87%	-0.14%	-2.62%	33.87%	7.75%	2.39%	6.22%	-14.20%	0.97%
Tax Burden Percent	87.55%	100.28%	100.33%	110.82%	102.49%	724.39%	74.43%	119.60%	68.00%	157.77%	41.69%
Interest Burden Percent	23.00%	117.87%	171.46%	-2.83%	-195.28%	40.83%	64.64%	1,320.95%	200.60%	198.82%	134.23%
Effective Tax Rate	12.45%	0.00%	0.00%	0.00%	0.00%	-624.39%	25.57%	-19.60%	32.00%	0.00%	58.31%
Return on Invested Capital (ROIC)	6.85%	-14.69%	-10.72%	6.22%	2.98%	87.27%	8.55%	6.49%	5.45%	-5.35%	0.97%
ROIC Less NNEP Spread (ROIC-NNEP)	15.54%	8.80%	18.37%	15.80%	22.94%	272.73%	-14.51%	-4.81%	14.42%	-114.62%	-0.12%
Return on Net Nonoperating Assets (RNNOA)	-5.90%	-2.66%	-6.37%	-6.37%	-6.24%	-57.41%	-2.33%	-2.26%	4.75%	-18.81%	-0.01%
Return on Equity (ROE)	0.95%	-17.35%	-17.10%	-0.16%	-3.26%	29.86%	6.22%	4.23%	10.20%	-24.16%	0.96%
Cash Return on Invested Capital (CROIC)	-41.45%	-18.04%	-20.14%	-3.60%	-44.23%	45.42%	-72.66%	5.57%	8.74%	18.84%	5.68%
Operating Return on Assets (OROA)	2.58%	-8.24%	-4.86%	2.28%	0.72%	4.67%	5.21%	0.11%	3.78%	-4.06%	0.89%
Return on Assets (ROA)	0.52%	-9.74%	-8.36%	-0.07%	-1.45%	13.82%	2.51%	1.69%	5.15%	-12.73%	0.50%
Return on Common Equity (ROCE)	0.95%	-17.35%	-17.10%	-0.16%	-3.26%	29.86%	6.22%	4.23%	10.20%	-24.16%	0.96%
Return on Equity Simple (ROE_SIMPLE)	0.85%	-17.33%	-15.25%	-0.15%	-3.10%	23.48%	5.75%	4.11%	9.64%	-25.58%	0.00%
Net Operating Profit after Tax (NOPAT)	8.28	-22	-17	11	7.34	336	67	72	60	-51	8.00
NOPAT Margin	3.32%	-8.11%	-6.09%	3.30%	1.74%	78.15%	12.36%	5.38%	4.42%	-3.66%	1.10%
Net Nonoperating Expense Percent (NNEP)	-8.68%	-23.49%	-29.10%	-9.59%	-19.96%	-185.46%	23.06%	11.30%	-8.97%	109.27%	1.09%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	4.90%	4.28%	-3.77%	0.75%
Cost of Revenue to Revenue	28.85%	39.84%	30.67%	25.75%	25.35%	27.31%	25.90%	14.94%	13.68%	12.16%	20.61%
SG&A Expenses to Revenue	55.84%	55.22%	56.34%	52.56%	47.69%	45.04%	36.81%	19.08%	19.96%	20.98%	50.76%
R&D to Revenue	11.51%	16.53%	19.99%	16.51%	17.13%	13.83%	10.26%	6.36%	5.65%	5.82%	16.15%
Operating Expenses to Revenue	67.35%	71.75%	78.03%	69.53%	72.17%	61.90%	57.49%	79.53%	77.60%	113.49%	76.74%
Earnings before Interest and Taxes (EBIT)	9.22	-32	-25	15	5.50	49	87	2.01	62	-63	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	-15	0.73	41	41	87	142	101	141	19	102
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.92	5.52	6.63	5.51	5.33	4.20	3.67	2.28	1.80	1.12	1.61
Price to Tangible Book Value (P/TBV)	15.06	7.01	8.26	6.82	12.52	6.14	0.00	24.84	7.01	2.47	3.65
Price to Revenue (P/Rev)	11.34	4.37	6.46	5.24	4.49	6.05	4.95	1.33	1.16	0.62	1.53
Price to Earnings (P/E)	1,520.80	0.00	0.00	0.00	0.00	17.86	63.85	0.00	167.68	0.00	158.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.07%	0.00%	0.00%	0.00%	0.00%	5.60%	1.57%	0.00%	0.60%	0.00%	0.63%
Enterprise Value to Invested Capital (EV/IC)	18.36	7.38	10.23	8.70	6.05	5.26	2.77	1.89	1.65	1.11	1.52
Enterprise Value to Revenue (EV/Rev)	11.06	4.14	6.08	4.85	4.37	5.69	5.63	1.58	1.31	0.67	1.69
Enterprise Value to EBITDA (EV/EBITDA)	108.96	0.00	2,374.63	39.90	45.39	27.99	21.53	20.91	12.58	50.46	12.05
Enterprise Value to EBIT (EV/EBIT)	298.75	0.00	0.00	108.84	334.25	49.70	34.97	1,045.54	28.81	0.00	97.43
Enterprise Value to NOPAT (EV/NOPAT)	332.73	0.00	0.00	146.81	250.78	7.28	45.59	29.33	29.73	0.00	153.11
Enterprise Value to Operating Cash Flow (EV/OCF)	98.29	34.20	98.00	33.47	26.09	31.74	24.27	14.49	11.46	4.94	8.06
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	13.99	0.00	34.20	18.55	5.17	26.15
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.48	0.50	0.99	0.91	0.86	0.75	1.44	0.89	0.60	0.75	0.54
Long-Term Debt to Equity	0.00	0.50	0.99	0.90	0.86	0.51	0.92	0.85	0.59	0.49	0.54
Financial Leverage	-0.38	-0.30	-0.35	-0.40	-0.27	-0.21	0.16	0.47	0.33	0.16	0.12
Leverage Ratio	1.83	1.78	2.05	2.19	2.25	2.16	2.48	2.50	1.98	1.90	1.92
Compound Leverage Factor	0.42	2.10	3.51	-0.06	-4.39	0.88	1.60	32.96	3.97	3.77	2.57
Debt to Total Capital	32.27%	33.18%	49.73%	47.53%	46.30%	42.75%	58.96%	47.08%	37.52%	42.92%	34.94%
Short-Term Debt to Total Capital	32.27%	0.00%	0.06%	0.06%	0.00%	13.83%	21.05%	2.30%	0.62%	14.80%	0.00%
Long-Term Debt to Total Capital	0.00%	33.18%	49.67%	47.47%	46.30%	28.92%	37.90%	44.78%	36.90%	28.13%	34.94%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.73%	66.82%	50.27%	52.47%	53.70%	57.25%	41.04%	52.92%	62.48%	57.08%	65.06%
Debt to EBITDA	4.12	-7.44	376.70	7.10	7.55	5.30	7.40	6.85	3.71	31.59	3.66
Net Debt to EBITDA	-2.71	4.37	-148.56	-3.25	-1.25	-1.77	2.62	3.34	1.46	3.51	1.10
Long-Term Debt to EBITDA	0.00	-7.44	376.26	7.09	7.55	3.58	4.76	6.51	3.65	20.70	3.66
Debt to NOPAT	12.57	-4.85	-15.84	26.11	41.72	1.38	15.68	9.60	8.76	-11.40	46.52
Net Debt to NOPAT	-8.26	2.85	6.25	-11.96	-6.91	-0.46	5.54	4.69	3.45	-1.27	13.93
Long-Term Debt to NOPAT	0.00	-4.85	-15.82	26.08	41.72	0.93	10.08	9.14	8.62	-7.47	46.52
Altman Z-Score	9.93	4.01	3.28	3.38	2.67	2.94	1.65	2.10	2.54	1.59	1.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.69	5.42	6.96	7.88	3.79	2.57	1.66	3.37	5.24	2.40	4.54
Quick Ratio	1.23	4.52	6.10	6.95	3.15	2.27	1.44	2.62	3.94	1.93	3.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-50	-28	-33	-6.45	-109	175	-569	62	96	181	47
Operating Cash Flow to CapEx	69.54%	135.39%	92.31%	336.71%	694.16%	203.78%	274.10%	483.02%	1,020.04%	1,780.64%	991.29%
Free Cash Flow to Firm to Interest Expense	-6.44	-3.90	-1.51	-0.29	-4.61	5.18	-17.92	1.54	1.76	117.91	2.54
Operating Cash Flow to Interest Expense	3.60	4.74	0.82	2.23	2.98	2.28	3.96	3.63	2.86	123.54	8.25
Operating Cash Flow Less CapEx to Interest Expense	-1.58	1.24	-0.07	1.57	2.55	1.16	2.52	2.88	2.58	116.60	7.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.70	0.71	0.56	0.51	0.55	0.41	0.32	0.71	0.83	0.90	0.52
Accounts Receivable Turnover	10.33	9.91	9.31	9.68	9.85	8.54	7.25	13.70	13.24	12.81	6.12
Inventory Turnover	1.58	2.37	2.42	1.93	2.00	1.91	1.72	2.05	1.84	1.48	1.08
Fixed Asset Turnover	3.30	2.89	2.76	3.13	3.95	3.56	3.33	7.17	7.55	8.22	4.72
Accounts Payable Turnover	9.27	13.55	7.93	5.98	7.86	10.10	13.37	15.47	11.95	9.79	8.74
Days Sales Outstanding (DSO)	35.34	36.84	39.22	37.69	37.07	42.72	50.34	26.65	27.57	28.49	59.64
Days Inventory Outstanding (DIO)	230.95	154.02	150.89	189.09	182.76	191.24	212.36	178.21	198.06	245.90	338.98
Days Payable Outstanding (DPO)	39.37	26.93	46.02	61.00	46.46	36.13	27.29	23.59	30.55	37.30	41.78
Cash Conversion Cycle (CCC)	226.92	163.93	144.09	165.78	173.37	197.83	235.40	181.27	195.08	237.09	356.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	150	155	170	188	304	465	1,101	1,111	1,076	843	805
Invested Capital Turnover	2.06	1.81	1.76	1.88	1.71	1.12	0.69	1.21	1.23	1.46	0.88
Increase / (Decrease) in Invested Capital	58	5.11	15	18	116	161	636	10	-36	-232	-39
Enterprise Value (EV)	2,754	1,144	1,743	1,636	1,840	2,445	3,051	2,106	1,772	935	1,225
Market Capitalization	2,823	1,208	1,852	1,769	1,890	2,600	2,680	1,769	1,567	870	1,113
Book Value per Share	$5.94	$5.85	$6.89	$7.81	$8.51	$14.26	$16.40	$17.03	$18.74	$16.86	$16.11
Tangible Book Value per Share	$5.10	$4.61	$5.53	$6.30	$3.62	$9.75	($0.87)	$1.56	$4.82	$7.63	$7.08
Total Capital	322	328	556	612	661	1,082	1,780	1,464	1,393	1,364	1,065
Total Debt	104	109	276	291	306	463	1,049	689	522	585	372
Total Long-Term Debt	0.00	109	276	291	306	313	675	656	514	384	372
Net Debt	-68	-64	-109	-133	-51	-154	371	336	205	65	111
Capital Expenditures (CapEx)	40	25	19	15	10	38	46	30	15	11	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	48	26	24	34	8.93	26	63	96	143	152	189
Debt-free Net Working Capital (DFNWC)	207	198	335	418	301	548	720	384	421	637	427
Net Working Capital (NWC)	103	198	335	417	301	398	345	351	413	435	427
Net Nonoperating Expense (NNE)	6.42	16	25	12	18	190	25	40	-24	148	0.97
Net Nonoperating Obligations (NNO)	-68	-64	-109	-133	-51	-154	371	336	205	65	111
Total Depreciation and Amortization (D&A)	16	17	26	26	35	38	54	99	79	82	89
Debt-free, Cash-free Net Working Capital to Revenue	19.22%	9.28%	8.33%	10.14%	2.12%	6.12%	11.67%	7.17%	10.57%	10.87%	26.01%
Debt-free Net Working Capital to Revenue	83.07%	71.73%	116.95%	123.83%	71.46%	127.53%	132.89%	28.81%	31.20%	45.44%	58.84%
Net Working Capital to Revenue	41.28%	71.73%	116.84%	123.73%	71.46%	92.70%	63.70%	26.29%	30.56%	31.04%	58.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.05	($1.02)	($1.07)	($0.01)	($0.27)	$3.41	$0.95	$0.35	$0.91	($2.15)	$0.16
Adjusted Weighted Average Basic Shares Outstanding	36.54M	37.24M	39.81M	41.23M	42.03M	42.67M	44.26M	45.52M	46.22M	46.25M	44.57M
Adjusted Diluted Earnings per Share	$0.04	($1.02)	($1.07)	($0.01)	($0.27)	$3.33	$0.92	$0.34	$0.89	($2.15)	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	41.30M	37.24M	39.81M	41.23M	42.03M	43.68M	45.63M	46.54M	51.98M	46.25M	45.04M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.01)	($0.27)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.05M	37.53M	40.71M	40.91M	41.51M	43.86M	44.85M	45.95M	46.50M	46.28M	40.49M
Normalized Net Operating Profit after Tax (NOPAT)	8.28	-22	-14	12	25	36	67	42	60	177	23
Normalized NOPAT Margin	3.32%	-8.11%	-4.90%	3.63%	5.94%	8.39%	12.36%	3.15%	4.42%	12.64%	3.21%
Pre Tax Income Margin	0.85%	-13.69%	-14.82%	-0.13%	-2.55%	4.68%	10.42%	1.99%	9.14%	-9.00%	2.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.19	-4.55	-1.14	0.68	0.23	1.46	2.75	0.05	1.14	-41.41	0.68
NOPAT to Interest Expense	1.06	-3.17	-0.80	0.51	0.31	9.95	2.11	1.80	1.10	-33.50	0.43
EBIT Less CapEx to Interest Expense	-4.00	-8.05	-2.02	0.02	-0.20	0.34	1.30	-0.70	0.86	-48.35	-0.15
NOPAT Less CapEx to Interest Expense	-4.12	-6.67	-1.69	-0.15	-0.12	8.83	0.66	1.04	0.82	-40.44	-0.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.83%	3.69%	1.39%	-17.25%	2,139.81%

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	43,021,275.00	40,489,894.00	39,347,924.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	43,021,275.00	40,489,894.00	39,347,924.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	0.04	0.07	0.12
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.08%	4.23%	5.05%	2.83%	3.74%	1.08%	1.73%	6.49%	5.14%	5.00%	6.24%
EBITDA Growth	212.17%	77.68%	-19.42%	-425.28%	111.97%	-11.68%	-45.76%	123.73%	-51.30%	5.99%	7.34%
EBIT Growth	113.64%	520.93%	-28.80%	-907.27%	352.93%	-51.04%	-107.94%	104.48%	-91.21%	5.88%	288.97%
NOPAT Growth	435.42%	501.96%	-46.28%	-942.66%	-25.55%	-87.35%	-59.19%	103.72%	-56.79%	266.11%	30.62%
Net Income Growth	1,050.77%	145.96%	-26.69%	-1,421.29%	-224.98%	-46.41%	-125.66%	103.79%	-89.79%	-39.40%	196.00%
EPS Growth	405.26%	144.19%	-23.53%	-1,452.17%	-34.48%	-47.37%	-128.21%	103.86%	-86.84%	-30.00%	209.09%
Operating Cash Flow Growth	13.20%	156.70%	22.38%	21.34%	-30.37%	-27.78%	-77.44%	12.82%	31.86%	-27.58%	378.36%
Free Cash Flow Firm Growth	445.23%	2,839.88%	7.20%	113.16%	321.65%	94.45%	78.03%	-91.01%	-81.61%	-64.54%	17.19%
Invested Capital Growth	-3.23%	-7.85%	-6.84%	-22.02%	-21.58%	-18.08%	-15.01%	-1.07%	-4.60%	-7.40%	-20.60%
Revenue Q/Q Growth	422.32%	-80.48%	6.53%	-5.31%	426.90%	-80.98%	7.21%	-0.87%	9.67%	-9.90%	8.47%
EBITDA Q/Q Growth	-26.17%	19.63%	48.68%	-347.72%	148.11%	-50.15%	-8.70%	8.36%	-31.88%	46.69%	-6.03%
EBIT Q/Q Growth	-55.44%	69.32%	116.05%	-595.19%	125.00%	-81.70%	-135.05%	379.11%	-65.32%	212.13%	-37.45%
NOPAT Q/Q Growth	100.41%	-62.56%	67.62%	-769.95%	117.71%	-93.64%	440.89%	-39.01%	84.88%	-39.97%	92.97%
Net Income Q/Q Growth	515.44%	-86.56%	110.34%	-859.64%	41.78%	105.76%	-200.73%	212.07%	-69.86%	78.13%	59.57%
EPS Q/Q Growth	152.17%	-67.24%	105.26%	-897.44%	112.22%	-73.68%	-210.00%	209.09%	-58.33%	40.00%	71.43%
Operating Cash Flow Q/Q Growth	7.08%	3.19%	8.42%	1.28%	-38.55%	7.02%	-66.12%	406.44%	-28.18%	-41.22%	123.75%
Free Cash Flow Firm Q/Q Growth	105.51%	65.96%	-8.33%	57.03%	76.48%	-23.46%	-16.07%	-92.07%	258.55%	48.61%	177.40%
Invested Capital Q/Q Growth	-0.91%	-2.37%	-2.11%	-17.65%	-0.35%	2.00%	1.55%	-4.15%	-3.91%	-0.99%	-12.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	94.43%	71.63%	75.14%	76.95%	95.51%	79.69%	77.43%	80.91%	79.53%	79.47%	77.05%
EBITDA Margin	3.14%	19.26%	26.88%	-70.32%	6.42%	16.83%	14.33%	15.67%	9.73%	15.84%	13.73%
Operating Margin	3.87%	7.91%	15.86%	-82.77%	2.78%	1.18%	4.69%	3.54%	1.19%	3.89%	2.22%
EBIT Margin	0.90%	7.81%	15.84%	-82.84%	3.93%	3.78%	-1.24%	3.48%	1.10%	3.82%	2.20%
Profit (Net Income) Margin	7.80%	5.37%	10.61%	-85.11%	-9.40%	2.85%	-2.68%	3.03%	0.83%	1.64%	2.42%
Tax Burden Percent	70.03%	65.83%	51.62%	103.32%	222.24%	55.27%	251.53%	57.03%	286.69%	58.34%	182.11%
Interest Burden Percent	1,237.79%	104.50%	129.73%	99.43%	-107.63%	136.22%	86.03%	152.34%	26.34%	73.86%	60.36%
Effective Tax Rate	29.97%	34.17%	48.38%	0.00%	0.00%	44.73%	0.00%	42.97%	-186.69%	41.66%	-82.11%
Return on Invested Capital (ROIC)	3.35%	6.45%	5.31%	-41.69%	2.84%	0.96%	4.86%	3.40%	3.00%	2.01%	3.85%
ROIC Less NNEP Spread (ROIC-NNEP)	19.44%	6.56%	7.25%	-67.81%	-71.71%	4.34%	-3.31%	5.15%	-2.74%	0.93%	-0.69%
Return on Net Nonoperating Assets (RNNOA)	6.40%	2.09%	1.91%	-15.04%	-11.76%	0.56%	-0.53%	0.72%	-0.33%	0.13%	-0.07%
Return on Equity (ROE)	9.75%	8.54%	7.21%	-56.72%	-8.92%	1.52%	4.33%	4.13%	2.68%	2.14%	3.78%
Cash Return on Invested Capital (CROIC)	8.74%	14.70%	12.56%	20.04%	18.84%	13.67%	8.54%	4.53%	5.68%	8.82%	25.07%
Operating Return on Assets (OROA)	0.75%	6.82%	6.86%	-37.68%	3.52%	3.35%	-1.09%	3.50%	0.57%	2.01%	1.18%
Return on Assets (ROA)	6.47%	4.69%	4.59%	-38.71%	-8.43%	2.52%	-2.37%	3.04%	0.43%	0.86%	1.30%
Return on Common Equity (ROCE)	9.75%	8.54%	7.21%	-56.72%	-8.92%	1.52%	4.33%	4.13%	2.68%	2.14%	3.78%
Return on Equity Simple (ROE_SIMPLE)	0.00%	12.60%	7.23%	-12.10%	0.00%	-25.46%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	23	8.70	15	-98	17	1.10	5.95	3.63	6.71	4.03	7.77
NOPAT Margin	2.71%	5.20%	8.19%	-57.94%	1.95%	0.65%	3.29%	2.02%	3.41%	2.27%	4.04%
Net Nonoperating Expense Percent (NNEP)	-16.09%	-0.11%	-1.94%	26.12%	74.55%	-3.38%	8.17%	-1.74%	5.75%	1.09%	4.54%
Return On Investment Capital (ROIC_SIMPLE)	1.67%	0.62%	-	-	1.27%	0.08%	0.44%	0.33%	0.63%	0.39%	0.75%
Cost of Revenue to Revenue	5.57%	28.37%	24.86%	23.05%	4.49%	20.31%	22.57%	19.09%	20.47%	20.53%	22.95%
SG&A Expenses to Revenue	7.69%	43.10%	38.27%	44.10%	8.96%	51.37%	48.91%	51.14%	51.61%	52.96%	47.72%
R&D to Revenue	2.27%	10.91%	11.42%	11.33%	2.69%	15.00%	15.57%	14.46%	19.20%	15.83%	15.72%
Operating Expenses to Revenue	87.05%	63.72%	59.27%	159.71%	124.95%	78.51%	72.74%	77.36%	78.34%	75.58%	74.83%
Earnings before Interest and Taxes (EBIT)	7.71	13	28	-140	35	6.39	-2.24	6.25	2.17	6.77	4.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	27	32	48	-119	57	28	26	28	19	28	26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.80	1.52	1.51	0.93	1.12	1.44	1.46	1.59	1.61	1.40	1.49
Price to Tangible Book Value (P/TBV)	7.01	5.23	5.09	2.24	2.47	3.36	3.51	3.57	3.65	3.26	2.72
Price to Revenue (P/Rev)	1.16	1.00	1.93	1.00	0.62	0.82	0.79	0.82	1.53	1.25	1.34
Price to Earnings (P/E)	167.68	35.89	20.94	0.00	0.00	0.00	0.00	0.00	158.29	178.10	68.20
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.60%	2.79%	4.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.63%	0.56%	1.47%
Enterprise Value to Invested Capital (EV/IC)	1.65	1.44	1.44	0.93	1.11	1.41	1.40	1.51	1.52	1.33	1.57
Enterprise Value to Revenue (EV/Rev)	1.31	1.12	2.14	1.14	0.67	0.86	0.87	0.89	1.69	1.44	1.46
Enterprise Value to EBITDA (EV/EBITDA)	12.58	9.79	8.74	55.02	50.46	82.04	0.00	9.09	12.05	10.24	10.34
Enterprise Value to EBIT (EV/EBIT)	28.81	19.53	16.05	0.00	0.00	0.00	0.00	27.98	97.43	81.70	55.95
Enterprise Value to NOPAT (EV/NOPAT)	29.73	21.21	25.35	0.00	0.00	0.00	0.00	43.59	153.11	112.46	65.92
Enterprise Value to Operating Cash Flow (EV/OCF)	11.46	8.21	7.62	3.88	4.94	6.89	9.09	8.97	8.06	7.44	5.79
Enterprise Value to Free Cash Flow (EV/FCFF)	18.55	9.42	11.06	4.09	5.17	9.28	15.05	33.23	26.15	14.48	5.53
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.60	0.58	0.67	0.78	0.75	0.73	0.77	0.52	0.54	0.56	0.54
Long-Term Debt to Equity	0.59	0.57	0.67	0.51	0.49	0.48	0.50	0.52	0.54	0.56	0.54
Financial Leverage	0.33	0.32	0.26	0.22	0.16	0.13	0.16	0.14	0.12	0.14	0.10
Leverage Ratio	1.98	1.87	1.89	1.93	1.90	1.88	1.95	1.91	1.92	1.92	1.95
Compound Leverage Factor	24.49	1.96	2.45	1.92	-2.04	2.55	1.67	2.91	0.50	1.42	1.17
Debt to Total Capital	37.52%	36.84%	40.13%	43.93%	42.92%	42.22%	43.38%	34.13%	34.94%	35.99%	35.08%
Short-Term Debt to Total Capital	0.62%	0.61%	0.00%	15.07%	14.80%	14.62%	15.12%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	36.90%	36.23%	40.13%	28.86%	28.13%	27.59%	28.25%	34.13%	34.94%	35.99%	35.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	62.48%	63.16%	59.87%	56.07%	57.08%	57.79%	56.62%	65.87%	65.06%	64.01%	64.92%
Debt to EBITDA	3.71	3.36	3.48	40.85	31.59	39.50	-81.46	2.70	3.66	3.56	3.46
Net Debt to EBITDA	1.46	1.02	0.88	6.73	3.51	4.18	-16.25	0.79	1.10	1.38	0.84
Long-Term Debt to EBITDA	3.65	3.30	3.48	26.84	20.70	25.82	-53.06	2.70	3.66	3.56	3.46
Debt to NOPAT	8.76	7.28	10.09	-12.93	-11.40	-9.85	-7.95	12.95	46.52	39.09	22.03
Net Debt to NOPAT	3.45	2.21	2.54	-2.13	-1.27	-1.04	-1.59	3.79	13.93	15.17	5.35
Long-Term Debt to NOPAT	8.62	7.16	10.09	-8.49	-7.47	-6.44	-5.18	12.95	46.52	39.09	22.03
Altman Z-Score	2.43	2.32	1.84	0.79	1.80	1.93	1.91	2.53	1.93	1.79	1.92
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.24	5.81	6.82	2.25	2.40	2.41	2.38	5.26	4.54	4.73	5.04
Quick Ratio	3.94	4.58	5.49	1.81	1.93	1.90	1.79	3.38	3.01	3.01	3.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	59	98	90	141	249	191	160	13	46	68	188
Operating Cash Flow to CapEx	2,646.50%	1,731.35%	3,348.18%	1,317.69%	1,564.31%	414.82%	445.38%	1,571.94%	20,040.83%	942.73%	4,300.90%
Free Cash Flow to Firm to Interest Expense	2.91	29.61	0.00	30.14	0.00	41.68	34.13	2.41	11.70	18.30	51.84
Operating Cash Flow to Interest Expense	2.34	14.81	0.00	11.50	0.00	7.74	2.56	11.56	11.23	6.94	15.86
Operating Cash Flow Less CapEx to Interest Expense	2.25	13.95	0.00	10.63	0.00	5.88	1.98	10.83	11.17	6.21	15.50
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.83	0.87	0.43	0.45	0.90	0.89	0.88	1.01	0.52	0.53	0.54
Accounts Receivable Turnover	13.24	13.93	6.77	7.03	12.81	13.60	12.84	13.13	6.12	6.38	6.05
Inventory Turnover	1.84	1.93	1.83	1.71	1.48	1.36	1.22	1.11	1.08	1.07	1.10
Fixed Asset Turnover	7.55	7.68	3.95	4.06	8.22	8.35	8.68	9.02	4.72	4.89	5.23
Accounts Payable Turnover	11.95	13.95	8.34	9.94	9.79	9.79	6.30	8.06	8.74	8.17	6.51
Days Sales Outstanding (DSO)	27.57	26.21	53.89	51.89	28.49	26.83	28.43	27.79	59.64	57.21	60.36
Days Inventory Outstanding (DIO)	198.06	189.17	199.26	213.37	245.90	267.44	298.31	329.40	338.98	341.46	332.57
Days Payable Outstanding (DPO)	30.55	26.16	43.75	36.74	37.30	37.30	57.92	45.28	41.78	44.69	56.03
Cash Conversion Cycle (CCC)	195.08	189.22	209.41	228.53	237.09	256.97	268.82	311.92	356.83	353.99	336.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,076	1,050	1,028	846	843	860	874	837	805	797	694
Invested Capital Turnover	1.23	1.24	0.65	0.72	1.46	1.47	1.48	1.68	0.88	0.89	0.95
Increase / (Decrease) in Invested Capital	-36	-89	-75	-239	-232	-190	-154	-9.07	-39	-64	-180
Enterprise Value (EV)	1,772	1,517	1,480	791	935	1,212	1,222	1,268	1,225	1,058	1,087
Market Capitalization	1,567	1,359	1,332	694	870	1,150	1,107	1,158	1,113	915	998
Book Value per Share	$18.74	$19.19	$18.89	$16.25	$16.86	$17.26	$16.36	$16.18	$16.11	$16.15	$17.08
Tangible Book Value per Share	$4.82	$5.59	$5.62	$6.71	$7.63	$7.39	$6.80	$7.22	$7.08	$6.94	$9.32
Total Capital	1,393	1,412	1,469	1,337	1,364	1,382	1,338	1,104	1,065	1,022	1,035
Total Debt	522	520	589	587	585	583	580	377	372	368	363
Total Long-Term Debt	514	512	589	386	384	381	378	377	372	368	363
Net Debt	205	158	149	97	65	62	116	110	111	143	88
Capital Expenditures (CapEx)	1.80	2.84	1.59	4.09	2.12	8.55	2.70	3.87	0.22	2.72	1.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	143	132	135	131	152	154	189	209	189	204	242
Debt-free Net Working Capital (DFNWC)	421	458	540	585	637	647	635	456	427	406	493
Net Working Capital (NWC)	413	450	540	384	435	445	432	456	427	406	493
Net Nonoperating Expense (NNE)	-44	-0.28	-4.31	46	101	-3.71	11	-1.80	5.07	1.11	3.12
Net Nonoperating Obligations (NNO)	205	158	149	97	65	62	116	110	111	143	22
Total Depreciation and Amortization (D&A)	19	19	20	21	22	22	28	22	17	21	22
Debt-free, Cash-free Net Working Capital to Revenue	10.57%	9.76%	19.60%	18.88%	10.87%	10.95%	13.43%	14.77%	26.01%	27.76%	32.46%
Debt-free Net Working Capital to Revenue	31.20%	33.78%	78.16%	84.18%	45.44%	46.11%	45.13%	32.14%	58.84%	55.27%	66.10%
Net Working Capital to Revenue	30.56%	33.14%	78.16%	55.19%	31.04%	31.72%	30.74%	32.14%	58.84%	55.27%	66.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.55	$0.19	$0.41	($3.11)	$0.36	$0.10	($0.11)	$0.12	$0.05	$0.07	$0.12
Adjusted Weighted Average Basic Shares Outstanding	46.22M	46.50M	46.17M	46.13M	46.25M	46.28M	45.46M	44.04M	44.57M	40.46M	39.46M
Adjusted Diluted Earnings per Share	$0.58	$0.19	$0.39	($3.11)	$0.38	$0.10	($0.11)	$0.12	$0.05	$0.07	$0.12
Adjusted Weighted Average Diluted Shares Outstanding	51.98M	52.19M	50.54M	46.13M	46.25M	46.53M	45.46M	44.46M	45.04M	40.91M	40.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.50M	46.55M	46.13M	46.17M	46.28M	46.30M	44.93M	43.02M	40.49M	39.35M	39.86M
Normalized Net Operating Profit after Tax (NOPAT)	23	9.95	16	15	17	4.52	6.39	7.50	1.99	4.03	2.99
Normalized NOPAT Margin	2.71%	5.95%	8.98%	9.11%	1.95%	2.68%	3.53%	4.18%	1.01%	2.27%	1.55%
Pre Tax Income Margin	11.14%	8.16%	20.55%	-82.37%	-4.23%	5.15%	-1.06%	5.31%	0.29%	2.82%	1.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.38	3.94	0.00	-29.78	0.00	1.40	-0.48	1.19	0.56	1.83	1.17
NOPAT to Interest Expense	1.14	2.62	0.00	-20.83	0.00	0.24	1.27	0.69	1.72	1.09	2.15
EBIT Less CapEx to Interest Expense	0.29	3.08	0.00	-30.65	0.00	-0.47	-1.05	0.45	0.50	1.09	0.80
NOPAT Less CapEx to Interest Expense	1.05	1.77	0.00	-21.70	0.00	-1.63	0.69	-0.05	1.67	0.35	1.78
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	1.39%	0.00%	54.02%	-37.86%	-17.25%	0.00%	-22.04%	-130.93%	2,139.81%	3,903.44%	1,037.41%

Financials Breakdown Chart

Key Financial Trends

Pacira BioSciences (NASDAQ: PCRX) entered Q1 2026 with a much stronger operating profile than a year ago, but the quarter also showed the company remains heavily influenced by financing activity and non-cash items. Revenue was broadly steady year over year, profitability was positive, and operating cash flow improved sharply. At the same time, the balance sheet still carries meaningful leverage, and the company continued to spend heavily on share repurchases and debt repayment.

Q1 2026 headline results: revenue was $177.4 million, up slightly from $168.9 million in Q1 2025. Net income came in at $2.9 million, versus a loss of $143.5 million in the prior-year quarter, which was distorted by a large impairment charge. Operating cash flow was strong at $25.7 million.

What stands out most is the improvement in core profitability. Gross profit reached $141.0 million, with gross margin of about 79.5% in Q1 2026, compared with about 79.7% a year earlier. Operating income improved to $6.9 million from $2.0 million in Q1 2025, showing the business is still generating solid margins even as SG&A and R&D remain large.

Cash generation improved meaningfully. Operating cash flow increased from $19.1 million in Q1 2025 to $25.7 million in Q1 2026. That said, the quarter’s cash increase was not driven by operations alone; cash also benefited from $22.5 million in investment maturities/sales, partially offset by capex and financing outflows.

Balance sheet trends were mixed. Cash and equivalents fell to $144.3 million from $283.6 million at the start of the year, and total cash plus short-term investments was $202.2 million. Total liabilities were $554.6 million, including $367.7 million of long-term debt. Equity remained positive at $653.9 million, but debt is still a significant part of the capital structure.

Longer-term, the company has repaired its earnings profile after a rough stretch in 2024. In 2024, Pacira was hit by large restructuring and impairment charges, including a major loss in Q3 2024 and a weak Q1 2025 comparison. In 2025 and now into 2026, those charges have largely moderated, making the recent quarters look much cleaner operationally.

Revenue growth resumed in Q1 2026, with sales rising to $177.4 million from $168.9 million a year ago.
Operating income improved to $6.9 million, showing the core business remains profitable.
Net income turned positive at $2.9 million versus a prior-year loss, helped by the absence of large one-time charges.
Operating cash flow strengthened to $25.7 million from $19.1 million in Q1 2025.
Gross margin remained high at roughly 79.5%, a sign of a healthy underlying product economics profile.
Quarterly revenue was only modestly higher year over year, suggesting growth is steady rather than explosive.
SG&A and R&D spending remain elevated, which limits operating leverage despite solid gross profit.
The company still relies on investment income and portfolio activity to support cash generation at times.
Long-term debt remains sizable at $367.7 million, leaving leverage a key risk to watch.
Cash declined sharply during the quarter to $144.3 million, in part due to share repurchases and debt repayment.

Bottom line: Pacira BioSciences looks materially healthier on an operating basis than it did during the volatile 2024 period. The company is generating profits again, operating cash flow is improving, and margins remain strong. However, investors should keep an eye on the debt load, capital allocation, and whether revenue growth can accelerate beyond low-single-digit gains.

08/23/26 03:47 PM ETAI Generated. May Contain Errors.

Pacira BioSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pacira BioSciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Pacira BioSciences' net income appears to be on an upward trend, with a most recent value of $7.03 million in 2025, rising from $1.86 million in 2015. The previous period was -$99.56 million in 2024. See where experts think Pacira BioSciences is headed by visiting Pacira BioSciences' forecast page.

Pacira BioSciences' total operating income in 2025 was $19.19 million, based on the following breakdown:

Total Gross Profit: $576.66 million
Total Operating Expenses: $557.47 million

Over the last 10 years, Pacira BioSciences' total revenue changed from $249.00 million in 2015 to $726.41 million in 2025, a change of 191.7%.

Pacira BioSciences' total liabilities were at $571.81 million at the end of 2025, a 26.2% decrease from 2024, and a 237.7% increase since 2015.

In the past 10 years, Pacira BioSciences' cash and equivalents has ranged from $35.94 million in 2016 to $585.58 million in 2021, and is currently $158.55 million as of their latest financial filing in 2025.

Over the last 10 years, Pacira BioSciences' book value per share changed from 5.94 in 2015 to 16.11 in 2025, a change of 171.2%.

Related Companies

Financial statements for NASDAQ:PCRX last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Financials

Financials Breakdown Chart

Key Financial Trends

Pacira BioSciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Financials

Annual Income Statements for Pacira BioSciences

Quarterly Income Statements for Pacira BioSciences

Annual Cash Flow Statements for Pacira BioSciences

Quarterly Cash Flow Statements for Pacira BioSciences

Annual Balance Sheets for Pacira BioSciences

Quarterly Balance Sheets for Pacira BioSciences

Annual Metrics And Ratios for Pacira BioSciences

Quarterly Metrics And Ratios for Pacira BioSciences

Financials Breakdown Chart

Key Financial Trends

Pacira BioSciences Financials - Frequently Asked Questions

When does Pacira BioSciences' financial year end?

How has Pacira BioSciences' net income changed over the last 10 years?

What is Pacira BioSciences' operating income?

How has Pacira BioSciences' revenue changed over the last 10 years?

How much debt does Pacira BioSciences have?

How much cash does Pacira BioSciences have?

How has Pacira BioSciences' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools